Troutman Sanders Represents Biotech Pharmapace in Acqusition by WuXi AppTec
SAN DIEGO – Troutman Sanders LLP advised Pharmapace, Inc., a San Diego-based clinical research services company that provides a full range of biometrics services for all phases of clinical trials, in its sale to WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company. Pharmapace will become a wholly-owned subsidiary of WuXi Clinical — the clinical CRO arm of WuXi AppTec — and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.
"Pharmapace is excited to join WuXi AppTec, a world-class organization with superior leadership and long history of success, a like-minded focus with a customer-centric approach, as well as a vision to enable every company to discover and develop drugs for the patients around the world,” said Dr. Larry Shen, President and CEO of Pharmapace, in a company press release. “This combination now allows us to leverage WuXi AppTec's vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission,"
Bardia Moayedi led the Troutman Sanders team advising Pharmapace in the sale. The team included Dean Longfield, Christine Kim and Justin Ferguson (Corporate); Robert Friedman and Joel Post (Tax); Jeff Banish (Benefits); Kristalyn Lee (Labor and Employment); and Wynter Deagle and Matthew Hrutkay (Litigation).
Troutman Sanders has a robust Emerging Growth Company and Venture Capital practice, assisting numerous start-ups and venture capital firms through all stages of their lifecycle from formation through their financing rounds and their eventual merger, acquisition or IPO exit.
About Troutman Sanders
With a diverse practice mix, workforce and footprint, Troutman Sanders has cultivated its reputation for a higher commitment to client care for over 120 years. Ideally positioned to
help clients across sectors realize their business goals, the firm’s 650 attorneys transact for growth, resolve mission-threatening disputes and navigate complex legal and regulatory challenges. See
troutman.com for more information.